Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Novel compounds for treatment of glaucoma disclosed in patent literature

July 7, 2005

Retisert launched for chronic noninfectious uveitis

July 6, 2005

First phase III study begins for Evizon in wet AMD

July 5, 2005

Oxigene updates vascular targeting programs in ophthalmology

July 1, 2005

Genaera reaches SPA agreement on phase III trials for Evizon

June 30, 2005

Pre-NDA meeting for AzaSite

June 30, 2005

Sucampo suspends tacrolimus eye drops development program

June 29, 2005

Duska acquires P2 receptor-based technology to treat glaucoma

June 21, 2005

Enzo acquires rights to drug candidate for treating uveitis

June 16, 2005

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

June 14, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...